Microneedle-based nanodrugs for tumor immunotherapy

Area of Science:

• Biomedical Engineering
• Immunology
• Nanotechnology

Background:

• Cancer immunotherapy faces challenges due to physical barriers and immunosuppressive tumor microenvironments.
• Microneedles provide a promising platform for drug and immunobiologic delivery.
• Nanodrugs loaded onto microneedles (NDMNs) present a novel strategy to enhance treatment efficacy.

Purpose of the Study:

• To review the pivotal role of microneedle-based nanodrugs (NDMNs) in advancing cancer immunotherapy.
• To summarize innovative microneedle design strategies, immune activation mechanisms, and nanodrug delivery approaches.
• To explore the clinical status, limitations, and future directions of NDMNs in tumor immunotherapy.

Main Methods:

• Comprehensive review of existing literature on microneedle technology and nanodrug delivery for cancer immunotherapy.
• Analysis of microneedle design principles, including structure, shape, and functionality for optimized drug release and penetration.
• Discussion of various nanodrug formulations (nanoparticles, vaccines, gene drugs, oncolytic viruses) utilized in NDMNs.

Main Results:

• NDMNs effectively penetrate skin barriers, enabling precise delivery of therapeutic agents to tumor sites or immunoactive regions.
• Optimized microneedle designs facilitate controlled drug release and efficient penetration, enhancing immune responses.
• NDMNs demonstrate potential in overcoming physical and immunological barriers associated with solid tumors.

Conclusions:

• Microneedle-based nanodrugs represent a significant advancement in overcoming challenges in solid tumor immunotherapy.
• Further research into NDMN design, drug loading, and clinical translation is crucial for realizing their full therapeutic potential.
• NDMNs hold promise for improving the efficacy and accessibility of cancer immunotherapies.